UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 35

Sortiert nach

A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Nature communications, 2021-09, Vol.12 (1), p.5503-5503, Article 5503

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Gastroenterology (New York, N.Y. 1943), 2021-01, Vol.160 (1), p.219-231.e1

2021

Link zum Volltext

Verfügbarkeit prüfen

Lean Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease

Gastroenterology & hepatology, 2021-04, Vol.17 (4), p.184-186

Gunn, Nadege T

2021

Link zum Volltext

Verfügbarkeit prüfen

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom

Clinics in liver disease, 2018-02, Vol.22 (1), p.109

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of hepatitis C virus therapy on metabolism and public health

Liver international, 2017-01, Vol.37 (S1), p.13-18

2017

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis

The American journal of gastroenterology, 2022-11, Vol.117 (11), p.1805-1815

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

The American journal of gastroenterology, 2021-12, Vol.116 (12), p.2399-2409

2021

Link zum Volltext

Verfügbarkeit prüfen

752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Link zum Volltext

Verfügbarkeit prüfen

Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies

Diagnostics (Basel), 2022-10, Vol.12 (11), p.2608

2022

Link zum Volltext

Verfügbarkeit prüfen

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Hepatology communications, 2021-07, Vol.5 (7), p.1201-1211

2021

Link zum Volltext

Verfügbarkeit prüfen

Developing a relationship with a liver transplant program

Clinical liver disease (Malden, Mass.), 2017-03, Vol.9 (3), p.73-76

2017

Link zum Volltext

Verfügbarkeit prüfen

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

The New England journal of medicine, 2021-03, Vol.384 (12), p.1113-1124

2021

Link zum Volltext

Verfügbarkeit prüfen

LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D

American journal of preventive cardiology, 2021-09, Vol.7, p.100263, Article 100263

2021

Link zum Volltext

Verfügbarkeit prüfen

The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis

Liver international, 2023-05, Vol.43 (5), p.964-974

2023

Link zum Volltext

Verfügbarkeit prüfen

SAT-398 - Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus

Journal of hepatology, 2023-06, Vol.78, p.S653-S654

2023

Link zum Volltext

Verfügbarkeit prüfen

Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus

Journal of hepatology, 2023-06, Vol.78, p.S653-S654

2023

Link zum Volltext

Verfügbarkeit prüfen

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Clinical gastroenterology and hepatology, 2024-01, Vol.22 (1), p.113-123.e9

2024

Link zum Volltext

Verfügbarkeit prüfen

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Clinical gastroenterology and hepatology, 2024-01, Vol.22 (1), p.102-112.e9

2024

Link zum Volltext

Verfügbarkeit prüfen

Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)

Journal of hepatology, 2020-08, Vol.73, p.S123

2020

Link zum Volltext

Verfügbarkeit prüfen

LBP01 - Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)

Journal of hepatology, 2020-08, Vol.73, p.S123-S123

2020

Link zum Volltext

Verfügbarkeit prüfen

Current and Emerging Treatments for Non-alcoholic Steatohepatitis

Current hepatology reports, 2020-12, Vol.19 (4), p.391-401

2020

Link zum Volltext

Verfügbarkeit prüfen

LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Journal of hepatology, 2020-08, Vol.73, p.S114-S115

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(32)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(17)
Life Sciences & Biomedicine
(16)
Gastroenterology & Hepatology
(13)
Humans
(10)
Liver Diseases
(8)
Fibrosis
(7)
Liver - Pathology
(7)
Biopsy
(6)
Liver
(6)
Patients
(6)
Cirrhosis
(5)
Fatty Liver
(5)
Male
(5)
Non-Alcoholic Fatty Liver Disease - Complications
(5)
Non-Alcoholic Fatty Liver Disease - Drug Therapy
(5)
Non-Alcoholic Fatty Liver Disease - Pathology
(5)
Treatment Outcome
(5)
Diabetes
(4)
Female
(4)
Inflammation
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes

Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis

Lean Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease

The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom

Impact of hepatitis C virus therapy on metabolism and public health

A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis

Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease

752-P: LIVRQNac (AXA1125) Enhances Insulin Sensitivity in Primary Human Hepatocytes and in Subjects with NAFLD and T2D

Accuracy of Noninvasive Diagnostic Tests for the Detection of Significant and Advanced Fibrosis Stages in Nonalcoholic Fatty Liver Disease: A Systematic Literature Review of the US Studies

Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

Developing a relationship with a liver transplant program

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

LIVRQNac (AXA1125) ENHANCES INSULIN SENSITIVITY IN PRIMARY HUMAN HEPATOCYTES AND IN SUBJECTS WITH NAFLD AND T2D

The use of current knowledge and non‐invasive testing modalities for predicting at‐risk non‐alcoholic steatohepatitis and assessing fibrosis

SAT-398 - Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus

Improvements in liver fibroinflammation (as assessed by corrected T1 [cT1]) with HTD1801 (berberine ursodeoxycholate) treatment in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study

Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study

Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)

LBP01 - Multifactorial effects of AXA1125 and AXA1957 observed on markers of metabolism, inflammation and fibrosis: a 16-week randomized placebo-controlled study in subjects with non-alcoholic fatty liver disease (NAFLD) with and without type 2 diabetes (T2D)

Current and Emerging Treatments for Non-alcoholic Steatohepatitis

The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH

LBO01 - Positive topline results from a 24-week, randomized, double-blind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitis

Suchergebnisse filtern